Cannabis Use Patterns Among Cancer Patients

Determining Patterns of Cannabis Use Among Cancer Patients

This study determines patterns of cannabis use among cancer patients. Information collected in this study may help doctors to understand patient use of cannabis therapy, their knowledge and experiences with this therapy, benefits and risks associated with its use, and whether or to what extent they are discussing it with their health care providers.

Study Overview

• Status: Completed
• Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
• Intervention / Treatment: Other: Survey Administration

Detailed Description

PRIMARY OBJECTIVES:

I. To identify the frequency, modes, and duration of cannabis use, assess experiences with obtaining and using cannabis, as well as reasons for use and perceived risks and benefits of its use among cancer patients who are undergoing or have recently completed active treatment.

Ia. To uncover disparities in use of cannabis, perceptions of use, and communication with providers among cancer patients who are identify as racial and ethnic minorities, have low health or digital literacy, are of older age or low socioeconomic status.

II. Among cancer patients with a known medical marijuana certification, assess the impact of cannabis on pain management, anxiety, anorexia, and quality of life, as well as their communication with their oncology team about their procurement and use of cannabis.

OUTLINE:

Patients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy.

• Study Type: Observational
• Enrollment (Actual): 1568

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Thomas Jefferson University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients who had at least one medical or radiation oncology appointment within last 3 years at Sidney Kimmel Cancer Center (SKCC) cancer centers

Description

Inclusion Criteria:

• Provide signed and dated informed consent form
• English speaking
• Willing to comply with all study procedures and be available for the duration of the study
• Any individual >= 18 years old
• At least one medical or radiation oncology appoint within the last 3 years at one of the SKCC cancer center campuses

Exclusion Criteria:

• Non-English speaking
• Not a cancer patient at one of the SKCC campuses
• Deceased

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Observational (survey); Patients complete a survey about knowledge and awareness of medical cannabis, perceived risks and benefits of cannabis, mode and frequency of use (if applicable), impact on cancer-related symptoms, patient provider discussions about cannabis, and demographic characteristics including health and digital literacy.	Other: Survey Administration; Complete a Survey

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survey data analysis	Respondent demographics and clinical characteristics and survey responses	Up to 12 months

Collaborators and Investigators

• Sponsor: Thomas Jefferson University
• Collaborators: National Cancer Institute (NCI)

Study record dates

Study Major Dates

• Study Start (Actual): February 25, 2021
• Primary Completion (Actual): October 29, 2022
• Study Completion (Actual): October 29, 2022

Study Registration Dates

• First Submitted: November 2, 2021
• First Submitted That Met QC Criteria: November 12, 2021
• First Posted (Actual): November 24, 2021

Study Record Updates

• Last Update Posted (Actual): May 15, 2025
• Last Update Submitted That Met QC Criteria: May 14, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: 21F.175; P30CA056036-21S3 (U.S. NIH Grant/Contract); JT 16464 (Other Identifier: JeffTrial Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No